Trump Administration Executive Order (EO) Tracker
Daniel Brook
Partner Intellectual Property
Languages
English
-
Overview
-
Experience
-
Credentials
-
Insights and events
Legal 500, 2018"Daniel Brook is ‘technically very competent’ and ‘gets the ins and outs of even the most complex piece of patent litigation’".
Daniel is a patent litigator in the UK. He acts for clients such as MSD, Lilly, Amgen and BMS. Recent key cases include Actavis v Lilly (Supreme Court), Schutz v Werit (Supreme Court), and BMS v Teva (availability of interim injunctions).
He has experience with each of the major patent jurisdictions in Europe. He regularly manages cross border patent litigation for clients on their most important products and has been involved in a number of leading cases.
Daniel is ranked by Chambers UK - 'Clients commend his 'high-quality counselling' and his 'clear, well-structured' communications.', Legal 500, MIP IP Stars, IAM Patent 1000 and Who's Who Legal.
Legal 500, 2018"Daniel Brook is ‘technically very competent’ and ‘gets the ins and outs of even the most complex piece of patent litigation’".
Representative experience
Acting for MSD in relation to patent challenges around its products including simvastatin, lovastatin, alendronate and raltegravir.
Acting for Lilly in relation to patent challenges around its oncology products including pemetrexed (Supreme Court) and gemcitabine.
Acting for BMS in relation to patent challenges around its products, dasatinib, efavirenz and atazanavir.
Acting for a number of electronic clients including HTC, ZTE and BlackBerry on European patent litigation matters.
Credentials
Education
- M.A. Natural Sciences - Chemistry, University of Cambridge, 1999
- M.Sci, University of Cambridge, 1999
Memberships
- AIPPI Council Member
- CIPA
- EPLAW
Recognition
Publications
Insights and Analysis
Court of Appeal grants Mylan stay of injunction pending appeal against validity of Neurim divisional
05 April 2022
Events
Webinar
10 March 2022 | 3:00 PM - 4:30 PM (JST)